Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, ...

JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1/gluc ...

SAFETY HARBOR, Fla., Sept. 24, 2024 /PRNewswire/ --- Integrated Ventures Inc. ("Company", "OTCQB: INTV") is pleased to announce that its newly launched subsidiary, MedWell USA, LLC has signed a strategic and valuable Management Services Organization ("MSO") agreement with FDA licensed manufacturer of pharmaceutical products. This agreement enables MedWell USA to act as a Procurement Agent for Semaglutide, a leading pharmaceutical product in the weight management sector. MedWell USA will leverage various mar ...

Educational panel available for free via the Life Time App 6:00-7:30 p.m. CT CHANHASSEN, Minn., Sept. 23, 2024 /PRNewswire/ -- With interest in and demand for GLP-1 peptides continuing to explode, Life Time (NYSE: LTH) announced today that it will host a complimentary, informational livestreamed panel on September 25. The event is available to everyone via the complimentary Life Time App, and features insights from Life Time Chief Science Officer James LaValle, MIORA Medical Director Dr. Gregory Pippert and ...

Terns has a modest market cap of less than $800 million, and its possible upside could be massive. Goldman Sachs projects that the anti-obesity market will be worth as much as $100 billion by the end of the decade. It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The best-selling glucagon-like peptide-1 (GLP-1) weight-loss treatments today are injections, but companies are working on pills which could be more attractive to patients, es ...

J Studios Introduction The telehealth company Hims & Hers (NYSE:HIMS) has seen its stock price range from under $6 to over $25 during the last 52 weeks. Since the stock price peaked in June, the stock has almost been cut in half. Back in May Hims surprised the market by announcing its affordable GLP-1 offering which immediately sent the stock soaring. However, recent news regarding Hims ability to continue with its GLP-1 offering beyond the temporary shortage has led to uncertainty around the stock. As of w ...

Omar Halawi/iStock via Getty Images I upgraded Becton, Dickinson and Company's (NYSE:BDX) to a 'Buy' rating in my previous article published in March 2024, arguing major growth challenges including Alaris pump and strong year-over-year comparables were fading away. I believe GLP-1 drug delivery could become a significant growth driver for the company in the near future. The company announced to acquire Edwards Lifesciences' (EW) Critical Care product group for $4.2 billion. I view the acquisition as value a ...

Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies Higher do ...

TAMPA, Fla., Sept. 4, 2024 /PRNewswire/ -- Integrated Ventures Inc. (OTCQB: INTV), a holdings company, focused on e-commerce technology, digital assets and consumer-focused investments, is excited to announce (1) formation and launch of our second, fully funded, 100% owned subsidiary - MedWellDirect, LLC, Direct-ToConsumer (D2C) telemedicine solutions provider, mainly for weight loss and GLP-1 products and (2) acquisition of 51% stake in GetTrim.Com (TM), owned by Healthy Lifestyle USA – an innovative telem ...

The advent of GLP-1 weight-loss treatments has inadvertently underscored the importance of protein in mitigating muscle loss. While taking GLP-1 meds may be out of reach of many consumers due to exorbitant out-of-pocket costs and limited health insurance coverage, the popularity of high protein diets like keto or carnivore continues to gain popularity as a natural method to lose weight. Adding beef can reap rewards to a diet, but it's also proven to reap financial rewards for retail/wholesale sector restaur ...